Kwangdong to market Apthera's breast cancer product NeuVax in Korea

Kwangdong Pharm said it has recently entered into a commercial license agreement with the U.S. based Apthera, Inc. for use of Apthera’s NeuVax, a peptide-based cancer immunotherapy product.

Under the agreement, Kwangdong will receive a license to sell NeuVax in Korea for the treatment of early-stage breast cancer. Apthera will receive milestone payments as well as a royalty on commercial sal...